
Sign up to save your podcasts
Or


The averages rose to start the week and Jim Cramer is helping investors navigate the market's moves. First up, fresh off the announcement that Merck will buy Prometheus Biosciences for $11b, Cramer's talking to Merck CEO Rob Davis and Prometheus CEO Mark McKenna to dig deeper into what the deal will mean for investors and patients. Then, the S&P has climbed 8% this year, but is more upside ahead? Cramer's going Off The Charts to find out. Plus, Cramer's exclusive with InMode CEO Moshe Mizrahy.
Mad Money Disclaimer
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
By CNBC4.3
38963,896 ratings
The averages rose to start the week and Jim Cramer is helping investors navigate the market's moves. First up, fresh off the announcement that Merck will buy Prometheus Biosciences for $11b, Cramer's talking to Merck CEO Rob Davis and Prometheus CEO Mark McKenna to dig deeper into what the deal will mean for investors and patients. Then, the S&P has climbed 8% this year, but is more upside ahead? Cramer's going Off The Charts to find out. Plus, Cramer's exclusive with InMode CEO Moshe Mizrahy.
Mad Money Disclaimer
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

3,221 Listeners

1,362 Listeners

239 Listeners

149 Listeners

950 Listeners

325 Listeners

295 Listeners

67 Listeners

155 Listeners

2,157 Listeners

595 Listeners

552 Listeners

20 Listeners

1,559 Listeners

208 Listeners

412 Listeners

305 Listeners

123 Listeners

807 Listeners

179 Listeners

61 Listeners

160 Listeners

36 Listeners

12 Listeners

23 Listeners

11 Listeners

16 Listeners